Search results for "Lymphatic"

showing 10 items of 1179 documents

Functional characterization of the sea urchin sns chromatin insulator in erythroid cells.

2005

Abstract Chromatin insulators are regulatory elements that determine domains of genetic functions. We have previously described the characterization of a 265 bp insulator element, termed sns, localized at the 3′ end of the early histone H2A gene of the sea urchin Paracentrotus lividus. This sequence contains three cis-acting elements (Box A, Box B, and Box C + T) all needed for the enhancer-blocking activity in both sea urchin and human cells. The goal of this study was to further characterize the sea urchin sns insulator in the erythroid environment. We employed colony assays in human (K562) and mouse (MEL) erythroid cell lines. We tested the capability of sns to interfere with the communi…

animal structuresGlobin enhancerChromatin insulator; Enhancer blocking; Erythroid transcription factor; Globin enhancerSp1 Transcription FactorSettore BIO/11 - Biologia MolecolareElectrophoretic Mobility Shift AssayDNA-binding proteinParacentrotus lividusCell LineMiceErythroid Cellshemic and lymphatic diseasesbiology.animalHistone H2AAnimalsHumansGATA1 Transcription FactorChromatin insulatorEnhancerMolecular BiologySea urchinTranscription factorbiologyGene Transfer TechniquesGATA1Cell BiologyHematologybiology.organism_classificationLocus Control RegionMolecular biologyChromatinChromatinCell biologyGlobinsEnhancer Elements GeneticSea UrchinsParacentrotusMolecular MedicineEnhancer blockingInsulator ElementsErythroid transcription factorOctamer Transcription Factor-1Blood cells, moleculesdiseases
researchProduct

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

2021

International audience; Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by anti-ADAMTS13 autoantibodies inducing a severe deficiency of ADAMTS13. Epitope mapping studies on samples obtained during acute iTTP episodes have shown that the iTTP immune response is polyclonal, with almost all patients having autoantibodies targeting the spacer domain of ADAMTS13.Objectives To identify the immunogenic hotspots in the spacer domain of ADAMTS13.Patients/methods A library of 11 full-length ADAMTS13 spacer hybrids was created in which amino acid regions of the spacer domain of ADAMTS13 were exchanged by the corresponding region of the spacer domain of ADAMTS1. Next, th…

autoantibodiesADAMTS13 Protein030204 cardiovascular system & hematologyEpitope03 medical and health sciencesEpitopes0302 clinical medicineVon Willebrand factorimmunophenotypinghemic and lymphatic diseasesHumansthrombotic thrombocytopenic purpurachemistry.chemical_classificationbiologyPurpura Thrombotic ThrombocytopenicAutoantibodyHematologyMolecular biologyADAMTS13ADAMTS133. Good healthAmino acidepitope mappingEpitope mappingchemistryPolyclonal antibodiesImmunoglobulin Gbiology.proteinDNA IntergenicAntibody[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Role of GATA-1 and HSP70 in the Dyserythropoiesis of Early Myelodysplastic Syndromes.

2009

Abstract Abstract 3823 Poster Board III-759 Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem cell disorders characterized by a hypercellular dysplastic bone marrow (BM) with peripheral blood cytopenias, mainly anemia. Early MDS with less than 10% BM blasts which belong in most cases to low and intermediate-1 (int-1) risk groups according to the International Prognostic Scoring System (IPSS), usually demonstrate dyserythropoiesis. The growth of erythroid progenitors is altered, with increased caspase activation leading to excessive cell death, and cellular dysplasia characterized, in liquid culture of CD34+-derived erythroid progenitors, by a delayed expression of the gly…

biologyCellular differentiationImmunologyHematopoietic stem cellCaspase 3Cell BiologyHematologyFas receptorBiochemistryMolecular biologymedicine.anatomical_structureApoptosishemic and lymphatic diseasesbiology.proteinmedicineCancer researchEctopic expressionProgenitor cellCaspaseBlood
researchProduct

A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab′) 2 fragments (5S IVIG) and Fc fragments…

1997

During the past few decades intravenous immunoglobulin (IVIG) has been used successfully in the treatment of various immunoregulatory disorders. Treatment results have been attributed to immunomodulation mainly via Fc receptors or by anti-idiotypic antibodies to disease-causing autoantibodies. From the present study it is clearly evident that 7S IVIG (intact immunoglobulin) as well as 5S IVIG [F(ab')2 fragments] and Fc fragments have a potent immunomodulatory capacity. We demonstrate that mainly 7S IVIG inhibits alloantigen-induced T-cell proliferation and generation of cytotoxic T lymphocytes. Reduced interleukin-2 (IL-2) protein levels in culture supernatants of IVIG-supplemented mixed ly…

biologyChemistryLymphocytemedicine.medical_treatmentImmunologyPeripheral blood mononuclear cellIn vitromedicine.anatomical_structureCytokinehemic and lymphatic diseasesImmunologymedicinebiology.proteinImmunology and AllergyCytotoxic T cellAntibodyReceptorCytotoxicityImmunology
researchProduct

NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerabil…

2014

Abstract Chronic lymphocytic leukemia (CLL), the most frequent adult leukemia in Western countries, is characterized by progressive accumulation of mature, monoclonal B lymphocytes in blood, bone marrow, and lymphoid tissues. In the pathogenesis and treatment of CLL, B cell receptor (BCR) signaling plays a crucial role, and aberrations in downstream pathways that become activated in CLL need to be better defined. One downstream target of BCR signaling is NFATc1, a transcription factor with a high oncogenic and transforming potential. Employing a genome-wide comparative DNA methylation analysis the NFATc1 5’ region was identified to be DNA hypomethylated in CLL patient samples. The pilot ser…

biologyChronic lymphocytic leukemiaImmunologyB-cell receptorbreakpoint cluster regionPromoterCell BiologyHematologymedicine.diseaseBiochemistryCD19Leukemiahemic and lymphatic diseasesDNA methylationmedicineCancer researchbiology.proteinDNA hypomethylationBlood
researchProduct

The Histone Acetyl-Transferase MOZ Cooperates with the Histone Methyl-Transferase MLL to Regulate HOX Gene Expression in Human Hematopoietic Stem Cel…

2008

Abstract MOZ (MOnocytic leukaemia Zinc finger protein) (also called MYST3 or KAT6A) is a member of the MYST family of HATs which likely acetylate H4K16. The MLL (MixedLineageLeukemia) gene is a frequent target for recurrent chromosomal translocations found in AML and ALL. MLL (KMT2A) is a methyl-transferase targeting H3K4. It was shown that MOZ/CBP leukemia, as observed in MLL-rearranged leukemias, harbors abnormal levels of homeobox (HOX) genes expression. HOX transcription factors have a crucial function in hematopoiesis regulation. In addition, HOXA5, HOXA7, and HOXA9 are often considered to be pivotal HOX genes for MLL transformation, constituting downstream targets of MLL. In our study…

biologyImmunologyCell BiologyHematologyBiochemistryMYST3Molecular biologyHistone H3Histonehemic and lymphatic diseasesHistone methyltransferaseHistone methylationbiology.proteinH3K4me3WDR5Hox geneneoplasmsBlood
researchProduct

The CD38-Positive and CD38-Negative Subsets of CD34(high)-Positive Primary Acute Myeloid Leukemia Blasts Differ Considerably in the Expression of Imm…

2008

Abstract Acute myeloid leukemia (AML) is thought to arise from a rare putative ‘leukemic stem cell’ that is capable of self-renewal and formation of leukemic blasts. Serial xenotransplantation studies in immunodeficient mice have shown that this leukemia-initiating cell resides at very low numbers within CD34(high)-positive CD38-negative AML cells. Thus, immunotherapeutic approaches successfully eradicating this cell compartment should result in cure from disease. The objective of our study was to characterize the immune phenotype of the CD38-negative and CD38-positive subsets of primary CD34(high)-positive AML blasts ex vivo. We obtained therapeutic leukapheresis products from 17 AML patie…

biologyLineage markersImmunologyCD34hemic and immune systemsCell BiologyHematologyHuman leukocyte antigenmedicine.diseaseBiochemistryCD19Leukemiahemic and lymphatic diseasesbiology.proteinCancer researchmedicineCytotoxic T cellInterleukin-3 receptorCD8Blood
researchProduct

Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments

2021

Immune thrombocytopenia (ITP) is a rare autoimmune disease due to both a peripheral destruction of platelets and an inappropriate bone marrow production. Although the primary triggering factors of ITP remain unknown, a loss of immune tolerance—mostly represented by a regulatory T-cell defect—allows T follicular helper cells to stimulate autoreactive splenic B cells that differentiate into antiplatelet antibody-producing plasma cells. Glycoprotein IIb/IIIa is the main target of antiplatelet antibodies leading to platelet phagocytosis by splenic macrophages, through interactions with Fc gamma receptors (FcγRs) and complement receptors. This allows macrophages to activate autoreactive T cells …

biologybusiness.industryReviewHematologyComplement receptorAntibody opsonizationClassical complement pathwayImmune systemhemic and lymphatic diseasesImmunologybiology.proteinCytotoxic T cellMedicineDiseases of the blood and blood-forming organsPlateletRC633-647.5AntibodybusinessThrombopoietinHemaSphere
researchProduct

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

2004

Abstract The FLT3 receptor tyrosine kinase is expressed in 70-90% of cases of AML. Up to 35% of patients with AML show mutations in the JM-region or kinase domain of FLT3. These lead to autophosphorylation promoting ligand-independent cell proliferation and inhibition of apoptosis. Treatment with FLT3 tyrosine kinase inhibitors (TKI) is a promising tool in therapy of AML. Preliminary results investigating the FLT3-TKI PKC412 in patients with relapsed/refractory AML revealed that 11/15 patients (73%) with mutated FLT3 and 16/46 patients (35%) with WT FLT3 showed a >50% blast response in peripheral blood (Estey E et al. Blood.2003; 102:919a). Despite its remarkable efficacy in reducing…

biologymedicine.drug_classKinaseCell growthImmunologyAutophosphorylationClone (cell biology)Cell BiologyHematologyBiochemistryTyrosine-kinase inhibitorReceptor tyrosine kinasehemic and lymphatic diseasesImmunologymedicinebiology.proteinCancer researchPhosphorylationTyrosine kinaseBlood
researchProduct

A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report

2013

Key Clinical Message Acquired hemophilia A should be taken into account in the differential diagnosis of perioperative bleeding in patients without any apparent reason for activated partial thromboplastin time prolongation.

bleeding disordersPediatricsmedicine.medical_specialtymedicine.diagnostic_testAcquired hemophilia A; bleeding disorders; bypassing agentsbusiness.industryAcquired hemophilia ASettore MED/41 - AnestesiologiaAcquired hemophilia A bleeding disorders bypassing agents.Case ReportsGeneral MedicinePerioperativehemic and lymphatic diseasesAcquired hemophiliaMedicineIn patientDifferential diagnosisbusinessElderly patientbypassing agentsPartial thromboplastin time
researchProduct